Neuroimaging Modalities in Alzheimer’s Disease: Diagnosis and Clinical Features
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease causing progressive cognitive decline until eventual death. AD affects millions of individuals worldwide in the absence of effective treatment options, and its clinical causes are still uncertain. The onset of dementia symptoms indicates severe neurodegeneration has already taken place. Therefore, AD diagnosis at an early stage is essential as it results in more effective therapy to slow its progression. The current clinical diagnosis of AD relies on mental examinations and brain imaging to determine whether patients meet diagnostic criteria, and biomedical research focuses on finding associated biomarkers by using neuroimaging techniques. Multiple clinical brain imaging modalities emerged as potential techniques to study AD, showing a range of capacity in their preciseness to identify the disease. This review presents the advantages and limitations of brain imaging modalities for AD diagnosis and discusses their clinical value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 1×
“Studies have found alterations in this largescale functional network as the disease progresses, where AD patients display deficient network connectivity compared to normal controls [23,74,75].”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875 · cited 3×
“fMRI images examine the correlation between the BOLD signal and brain regions by comparing the cognitive condition to a control condition or by investigating functional connectivity during the resting state [33].”
BackgroundInfluentialComparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18 F-FDG PET of the Brain
Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., Lituiev, D., Copeland, T. P., Aboian, M. S., Mari Aparici, C., et al. (2019) · Radiology · doi:10.1148/radiol.2018180958 · Cited by 577
Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526 · cited 6×
“PET is used as a diagnostic tool to compare the scans of AD patient and non-patient groups to see the differences in uptake patterns [44].”
BackgroundMethodInfluentialMosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
Hippocampal hypometabolism predicts cognitive decline from normal aging
Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., Laska, E., Rusinek, H., & de Leon, M. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.008 · Cited by 360
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
Neuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289
Yoshizawa, H., Gazes, Y., Stern, Y., Miyata, Y., & Uchiyama, S. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2013.10.009 · Cited by 100 · cited 1×
“Although a decrease in glucose metabolism is also found in normal aging [51,52], the dementia caused by AD carries different metabolic changes.”
BackgroundAmini, M., Pedram, M. M., Moradi, A., & Ouchani, M. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/5514839 · Cited by 84 · cited 1×
“[79] utilized multiple machine learning methods for identifying disease severity, which achieved an accuracy and sensitivity up to 91.”
MethodCaselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
EEG Window Length Evaluation for the Detection of Alzheimer’s Disease over Different Brain Regions
Tzimourta, K. D., Giannakeas, N., Tzallas, A. T., Astrakas, L. G., Afrantou, T., Ioannidis, P., Grigoriadis, N., Angelidis, P., Tsalikakis, D. G., & Tsipouras, M. G. (2019) · Brain Sciences · doi:10.3390/brainsci9040081 · Cited by 79
Cited by
Mirkin, S., & Albensi, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1094233 · Cited by 46
Conklin, B., Conley, B. M., Hou, Y., Chen, M., & Lee, K.-B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114636 · Cited by 45
Odusami, M., Maskeliūnas, R., & Damaševičius, R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101496 · Cited by 42
“The fusion of various imaging modalities in multimodal neuroimaging holds the promise of offering comprehensive insights into the metabolic and structural changes occurring in AD [9,13,14].”
BackgroundKazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“Clinicians rely on clinical parameters, biomarkers, and imaging methods for diagnosis, with neuroimaging playing a crucial role in early detection [24,25].”
MethodAlam, M. M., & Latifi, S. (2025) · doi:10.20944/preprints202506.1854.v1 · Cited by 17
Metadata
- Authors
- Kim, J., Jeong, M., Stiles, W. R., & Choi, H. S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-05-28
- Volume
- 23
- Issue
- 11
- Pages
- 6079
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4281747958
- Cited by
- 124
- References
- 20
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.